Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Common Equity (2019 - 2025)

Historic Common Equity for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$1.9 billion.

  • BridgeBio Pharma's Common Equity fell 5857.35% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 5857.35%. This contributed to the annual value of -$1.5 billion for FY2024, which is 839.18% down from last year.
  • BridgeBio Pharma's Common Equity amounted to -$1.9 billion in Q3 2025, which was down 5857.35% from -$1.8 billion recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Common Equity high stood at -$389.4 million for Q1 2021, and its period low was -$1.9 billion during Q3 2025.
  • Over the past 5 years, BridgeBio Pharma's median Common Equity value was -$1.2 billion (recorded in 2023), while the average stood at -$1.2 billion.
  • In the last 5 years, BridgeBio Pharma's Common Equity plummeted by 91595.58% in 2021 and then soared by 1985.98% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Common Equity (Quarter) stood at -$867.0 million in 2021, then plummeted by 43.41% to -$1.2 billion in 2022, then dropped by 8.92% to -$1.4 billion in 2023, then decreased by 8.39% to -$1.5 billion in 2024, then tumbled by 31.69% to -$1.9 billion in 2025.
  • Its Common Equity was -$1.9 billion in Q3 2025, compared to -$1.8 billion in Q2 2025 and -$1.6 billion in Q1 2025.